Bli medlem
Bli medlem

Du är här



Press Release 10 November 2016

Financial summary

July - September 2016

· Net turnover totalled SEK 67.8 million (111.5 m), of which SEK
12.4 million (69.0 m) comprised royalties for simeprevir.

· Revenues from Medivir's own pharmaceutical sales totalled SEK 44.0
million (42.5 m), of which SEK 1.3 million (2.8 m) derived from sales
of OLYSIO® and SEK 42.7 million (39.7 m) from sales of other

· The profit after tax was SEK -50.4 million (-10.5 m).
· Basic and diluted earnings per share totalled SEK -1.87 (-0.39)
and SEK -1.87 (-0.39), respectively.

· The cash flow from operating activities amounted to SEK -37.0
million (75.4 m).

January - September 2016

· Net turnover totalled SEK 224.1 million (573.2 m), of which SEK
54.7 million (387.5 m) comprised the first three quarters' royalties
for simeprevir.

· Revenues from Medivir's own pharmaceutical sales totalled SEK
150.4 million (184.5 m), of which

SEK 9.1 million (50.3 m) derived from sales of OLYSIO® and SEK 141.3
million (134.2 m) from sales of other pharmaceuticals.

· The profit after tax was SEK -130.6 million (120.3 m).
· Basic and diluted earnings per share totalled SEK -4.85 (4.14) and
SEK -4.85 (4.11), respectively.

· The cash flow from operating activities amounted to SEK -110.5
million (345.0 m).

Significant events after the period end

· Medivir focuses exclusively on oncology and reorganises to
significantly reduce the cost structure.

· Enrolment to the phase IIa trial within the MIV-711 osteoarthritis
programme is complete and the independent safety review committee
recommends that the trial should go ahead.

· Medivir divests its pharmaceutical company, BioPhausia (Nordic
Brands) to Karo Pharma.

· Medivir's nucleotide polymerase inhibitor for the treatment of
liver cancer, MIV-818, enters non-clinical development.

· Medivir strengthens its clinical pipeline by signing an agreement
to acquire a portfolio of clinical phase oncology programmes.

Summary of the Group's Q3 Q1-Q3 Full year
figures (SEK m)
2016 2015 2016 2015 2015
Net turnover 67.8 111.5 224.1 573.2 657.9
Gross profit 48.7 90.2 159.0 487.9 548.6
Operating profit before -35.6 1.3 -108.0 190.9 155.0
depreciations (EBITDA)
Operating profit (EBIT) -44.4 -13.1 -133.3 159.2 114.8
Profit/loss before tax -40.4 -13.3 -122.0 155.0 102.0
Profit/loss after tax -50.4 -10.5 -130.6 120.3 75.1
Operating margin, % -65.5 -11.8 -59.5 27.8 17.4
Basic earnings per -1.87 -0.36 -4.85 4.14 2.59
share, SEK
Diluted earnings per -1.87 -0.36 -4.85 4.11 2.56
share, SEK
Net worth per share, 48.99 55.36 48.99 55.36 54.04
Return on equity -11.5 -0.9 -11.8 8.9 5.9
Cash flow from -37.0 75.4 -110.5 345.0 307.4
operating activities
Cash and cash 955.0 1 118.1 955.0 1 118.1 1 077.9
equivalents at period
R&D spending/total 75.9 68.1 73.4 63.3 52.8
opex, %

Conference call for investors, analysts and the media
The Interim Report, January - September 2016 will be presented by
Medivir's President & CEO,

Niklas Prager, and members of Medivir's management group.
Time: Thursday, 10 November 2016, at 14.00 (CEST).
Phone numbers for participants from:
Sweden: 08-566 426 96
Europe: +44 20 3008 9817
USA: +1 855 831 5946

The conference call will also be streamed via a link on the website:

The presentation will be available on Medivir's website after
completion of the conference.

CEO's comments
We continued to progress both our own portfolio research projects and
those that make up our partnered projects during the third quarter.

The MIV-711 osteoarthritis study was given the go-ahead to proceed,
based on a review of safety data, and the first patient was enrolled
in a continuation study. The completion of patient enrolment was,
announced after the quarter end, which means that we are on schedule
and have demonstrated our competence to design and run complex
clinical development projects. We consequently anticipate presenting
the results of the study in Q3 2017.

We also entered into a licensing agreement that gives Trek
Therapeutics exclusive rights to develop and commercialise the
MIV-802 project for the treatment of hepatitis C. The agreement not
only yields a one-off payment of SEK 10.3 million, it also entitles
Medivir to milestone payments based on successful clinical
development and royalties capped at a maximum of ca. 15% upon any
future commercialisation of products containing MIV-802.

Our partner, Janssen Research & Development, reported interesting
progress during the quarter of a phase IIa study with interim data
showing that the combination of simeprevir, odalasvir and AL-335 has
a high level of efficacy in HCV patients. The results show that 100%
of the patients treated with the triple combination achieved a
sustained viral response after as little as six weeks of treatment.
Simeprevir was shown to have a decisive effect and Jansen will
consequently continue its phase IIb studies by evaluating the effect
of using this triple combination for treatment of a broader group of
patients with different hepatitis C virus genotypes over periods of 6
and 8 weeks.

Royalties attributable to the hepatitis C pharmaceutical, OLYSIO®
(simeprevir), totalled SEK 12.4 million during the third quarter. Our
Nordic pharmaceutical sales saw the Nordic Brands portfolio achieve
revenues of SEK 42.1 million during the quarter, corresponding to an
increase of 8% in comparison with the same period in 2015.

Important decisions on Medivir's future orientation
Medivir continued to develop positively, overall, during the third
quarter, and several key decisions of great importance in terms of
Medivir's future orientation and development have also been taken
since the quarter ended.

One of the decisions announced was the reorganisation, along with
substantial cost reductions, in the early stage research portfolio
and in administrative functions. The reorganisation is expected to
result in a total cost reduction of approximately SEK 110 million per
year compared to levels under the current organisation. We also
decided to focus our operations exclusively on oncology. As a
consequence of these changes, a total of around 30 of Medivir's
employees will, unfortunately, have to leave the company.

We have also, as part of our efforts to achieve a more focused
approach, been working for some time now to separate the company's
operations into two independent companies, with the intention of
obtaining a separate listing for the new commercial company based on
the Nordic Brands portfolio. A number of proposals were received
during the in-depth evaluation of the potential for a separate
listing, and after a structured process during which the various
alternatives were compared, the Board decided that the sale of
BioPhausia AB to Karo Pharma would better serve the interests of
Medivir's shareholders than a separate listing.

We also announced, in early November, that we had acquired two
promising new clinical phase oncology projects. This constitutes a
fundamentally transformative transaction for Medivir and is an
important component of the strategy of broadening our pipeline with
later stage clinical phase programmes and shifting the emphasis from
early stage to clinical phase research, whilst simultaneously also
strengthening our focus on oncology.

We are also pleased to note that MIV-818 has been selected as a
candidate drug for the treatment of hepatocellular carcinoma (HCC)
and has now entered non-clinical development. MIV-818 is unique in
that it is the only orally administered chemotherapeutic being
developed specifically for liver cancers. It is extremely satisfying
to be able to deliver the first candidate drug from our internal
portfolio of early-stage anti-cancer and immune-oncology projects.

I am convinced that all of these new ventures and changes constitute
important steps in Medivir's transformation into an exclusively
oncology-focused pharmaceutical company and thereby further enhance
our ability to create long-term value.

Niklas Prager
President and CEO

Upcoming reporting dates:
Financial Statement (January - December 2016)
17 February 2017
Interim Report (January - March 2017)
28 April 2017
2017 Annual General Meeting
3 May 2017

For further information, please contact:
Niklas Prager, President & CEO, phone: +46 (0) 8 407 64 30
Ola Burmark, CFO, mobile: +46 (0)725-480 580.

Medivir is required under the Securities Markets Act to make the
information in this press release public.

The information was submitted for publication at 08.30 CET on 10
November 2016.

About Medivir
Medivir is a research based pharmaceutical company with a focus on
oncology and infectious diseases. We have a leading competence within
protease inhibitor design and nucleotide/nucleoside science and we
are dedicated to develop innovative pharmaceuticals that meet great
unmet medical need. Our commercial organization provides a portfolio
of specialty care pharmaceuticals on the Nordic market.

Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.